Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

MemorialCare Heart & Vascular Institute (MHVI), through its advanced research program, is participating in a CSL Behring-sponsored multi-center, Phase III clinical trial – "ApoA-I Event reducinG in Ischemic Syndromes II (AEGIS-II) – which is studying the removal of cholesterol from the arteries to reduce the risk of a second heart attack or stroke in patients.

News | Heart Failure

MemorialCare Heart and Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)

March 8, 2022 – MemorialCare Heart & Vascular Institute (MHVI), through its advanced research program, is participating ...

March 08, 2022

The same thing can be said for a heart with mitral valve prolapse (MVP) — as the diseased valve enlarges, the cords connected to the heart tissue feel stress and respond accordingly with stiffness and scarring, according to a recent paper in the Journal of the American Heart Association.

News | Heart Failure

Earlier Surgical Intervention Could Stave Off Fibrosis in People with Mitral Valve Prolapse

March 1, 2022 – The larger the sail, the more wind it catches. But as that size increases, so does the stress ...

March 01, 2022

News | Heart Failure

Adolescent Psychological Well-being Tied to Adult Risk of Cardiovascular Disease, Study Finds

March 1, 2022 – Scientists have known for years that a person’s risk of cardiovascular disease (CVD) can be lowered with ...

March 01, 2022

iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement of cardiac care, announced that the results of the KP-Rhythm2 study, titled “Diagnostic yield, outcomes and resource utilization with different ambulatory electrocardiographic monitoring strategies,” were published in the American Journal of Cardiology (AJC).

News | Atrial Fibrillation

Zio by iRhythm Shows Significantly Higher Documentation of Atrial Fibrillation and Atrial Flutter Compared to Holter Monitors, Event Monitors

February 28, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the ...

February 28, 2022

The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

News | Heart Failure

FDA Approves Empagliflozin for Reducing Risk of Heart Failure

February 24, 2022 — The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of ...

February 24, 2022

News | Cardiovascular Clinical Studies

Call for Entries!

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

February 17, 2022

Amir Sheikhi, assistant professor of chemical engineering and biomedical engineering, Penn State. Image credit: Penn State College of Engineering

News | Stroke

Researchers Aim to Improve Stroke Recovery with New Granular Biomaterials

February 16, 2022 – The Centers for Disease Control and Prevention estimate that someone in the United States has a ...

February 16, 2022

News | Pacemakers

'Bionic' Pacemaker Reverses Heart Failure

February 16, 2022 – A revolutionary pacemaker that re-establishes the heart’s naturally irregular beat is set to be ...

February 16, 2022

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.

News | Pulmonary Embolism

Could EKGs Help Doctors Use AI to Detect Pulmonary Embolisms?

February 14, 2022 — Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Ica ...

February 14, 2022

News | Heart Failure

Study Finds Higher Risk in Families of Black Patients with Inherited Muscle Disease

February 11, 2022 – Black patients diagnosed with dilated cardiomyopathy (DCM) of unknown cause are more likely to have ...

February 11, 2022

News | Heart Failure

‘Pop-up’ Electronic Sensors Could Detect When Individual Heart Cells Misbehave

February 11, 2022 — Engineers at the University of California San Diego have developed a powerful new tool that monitors ...

February 11, 2022

The American College of Cardiology will host the 71st Annual Scientific Session & Expo live, in person, in Washington, DC, April 2 – 4, 2022, and provides the opportunity to network with colleagues

Feature | ACC | By Melinda Taschetta-Millane

Keynote Speakers Announced for ACC 2022

The American College of Cardiology will host the 71st Annual Scientific Session & Expo live, in person, in Washington ...

February 11, 2022

Figure 1Recommended Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. ∗While not marketed in the United States, DCBs are available for clinical use in Canada, with 1-3 months of DAPT recommended. DAPT = dual antiplatelet therapy; LD, limited data. Reprinted from Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915-2931, with permission from

News | Womens Cardiovascular Health

SCAI Releases Expert Consensus on Gender-specific Considerations in Myocardial Revascularization

February 9, 2022 — A newly released expert consensus statement on sex-specific considerations in myocardial ...

February 09, 2022

Expression of SARS-CoV-2 receptors in human cardiac PCs in situ: Immunofluorescence stainings showing PCs in the human heart. (A,B) Identification of CD31−CD34+PDGFRβ+ PCs around microvessels. CD31 recognises the vessel lumen, the CD34 labels both the luminal ECs and perivascular PCs, while PDGFRβ labels both PCs and vascular smooth muscle cells (VSMCs) in the arteriole’s tunica media. (C–F) A subset of PDGFRβ+ cardiac PCs express ACE2 (C,D) and CD147 (E,F). α-SMA labels some PCs and arterioles’ VSMCs (C,D)

News | Coronavirus (COVID-19)

SARS-CoV-2 Spike Protein Binds to Heart’s Vascular Cells Potentially Contributing to Severe Microvascular Damage

February 9, 2022 — A new study has shown how SARS-CoV-2 may contribute to severe microvascular damage seen in severely ...

February 09, 2022

A new study is the first to show that a remote cognitive assessment could help with tracking patients with cardiovascular risk. Getty Images

News | Cardiovascular Clinical Studies

Study: Cognitive Assessments Can Help Track Cardio Risk

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

February 07, 2022